Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 4/2011

01.07.2011 | Clinical Investigation

Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization

verfasst von: Noriaki Shimada, Kyoko Ohno-Matsui, Kengo Hayashi, Takeshi Yoshida, Takashi Tokoro, Manabu Mochizuki

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the incidence and features of macular retinal detachment (RD) after successful intravitreal injection of bevacizumab (IVB) for the treatment of myopic choroidal neovascularizations (CNVs).

Methods

Seventy-four eyes of 74 patients who received IVB for myopic CNV were studied. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline, at 1 week after IVB, and every month thereafter. The shortest follow-up period was 6 months.

Results

Four eyes (5.4%) either developed or had increased macular RD after successful IVB. In the three eyes, macular RD newly developed 1 month after IVB despite the absence of dye leakage. The remaining eye had a limited area of macular RD at baseline and increased despite the disappearance of dye leakage from the CNV after the IVB. The four eyes that developed a macular RD had retinoschisis around the CNV before IVB, whereas none of the 70 other patients had a retinoschisis throughout the follow-up period. In all four eyes that either developed or had increased macular RD, outer lamellar holes were detected at the upper edge of the RD by OCT examinations, whereas none of the patients who did not develop a macular RD after IVB showed outer lamellar holes.

Conclusions

These results suggest that there is a risk of developing macular RD after IVB in eyes with myopic CNV. Periodic OCT examinations are recommended for patients with myopic CNV to search for RDs after IVB.
Literatur
1.
Zurück zum Zitat Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol. 1997;123:181–7.CrossRefPubMed Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol. 1997;123:181–7.CrossRefPubMed
2.
Zurück zum Zitat Curtin BJ. Ocular findings and complications. In: Curtin BJ, editor. The myopias. Philadelphia: Harper & Row; 1985. p. 277–347. Curtin BJ. Ocular findings and complications. In: Curtin BJ, editor. The myopias. Philadelphia: Harper & Row; 1985. p. 277–347.
3.
Zurück zum Zitat Panozzo G, Mercanti A. Optical coherence tomography findings in myopic traction maculopathy. Arch Ophthalmol. 2004;122:1455–60.CrossRefPubMed Panozzo G, Mercanti A. Optical coherence tomography findings in myopic traction maculopathy. Arch Ophthalmol. 2004;122:1455–60.CrossRefPubMed
4.
Zurück zum Zitat Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;1:42–53.CrossRef Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;1:42–53.CrossRef
5.
Zurück zum Zitat Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157–60.CrossRefPubMed Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157–60.CrossRefPubMed
6.
Zurück zum Zitat Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol. 2007;91:161–5.CrossRefPubMed Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol. 2007;91:161–5.CrossRefPubMed
7.
Zurück zum Zitat Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190–6.CrossRefPubMed Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190–6.CrossRefPubMed
8.
Zurück zum Zitat Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008;126:941–5.CrossRefPubMed Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008;126:941–5.CrossRefPubMed
9.
Zurück zum Zitat Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94–100.CrossRefPubMed Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94–100.CrossRefPubMed
10.
Zurück zum Zitat Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2010;149:458–64.CrossRefPubMed Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2010;149:458–64.CrossRefPubMed
11.
Zurück zum Zitat Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: 1-year results of a prospective study. Br J Ophthalmol. 2009;93:150–4.CrossRefPubMed Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: 1-year results of a prospective study. Br J Ophthalmol. 2009;93:150–4.CrossRefPubMed
12.
Zurück zum Zitat Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol. 2007;21:185–7.CrossRefPubMedPubMedCentral Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol. 2007;21:185–7.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Bando H, Ikuno Y, Choi JS, Tano Y, Yamanaka I, Ishibashi T. Ultrastructure of internal limiting membrane in myopic foveoschisis. Am J Ophthalmol. 2005;139:197–9.CrossRefPubMed Bando H, Ikuno Y, Choi JS, Tano Y, Yamanaka I, Ishibashi T. Ultrastructure of internal limiting membrane in myopic foveoschisis. Am J Ophthalmol. 2005;139:197–9.CrossRefPubMed
14.
Zurück zum Zitat Shimada N, Ohno-Matsui K, Yoshida T, Sugamoto Y, Tokoro T, Mochizuki M. Progression from macular retinoschisis to retinal detachment in highly myopic eyes is associated with outer lamellar hole formation. Br J Ophthalmol. 2008;92:762–4.CrossRefPubMedPubMedCentral Shimada N, Ohno-Matsui K, Yoshida T, Sugamoto Y, Tokoro T, Mochizuki M. Progression from macular retinoschisis to retinal detachment in highly myopic eyes is associated with outer lamellar hole formation. Br J Ophthalmol. 2008;92:762–4.CrossRefPubMedPubMedCentral
Metadaten
Titel
Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization
verfasst von
Noriaki Shimada
Kyoko Ohno-Matsui
Kengo Hayashi
Takeshi Yoshida
Takashi Tokoro
Manabu Mochizuki
Publikationsdatum
01.07.2011
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 4/2011
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-011-0034-2

Weitere Artikel der Ausgabe 4/2011

Japanese Journal of Ophthalmology 4/2011 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.